Association between polymorphisms of APE1 and OGG1 and risk of colorectal cancer in Taiwan

doi:10.3748/wjg.v22.i12.3372

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7517)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

488

WORD

290

HTML

3737

Tables (1-5)

291

Sum=4806

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

935

Download

1776

Sum=2711

Mar 28, 2016 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastroenterol. Mar 28, 2016; 22(12): 3372-3380
Published online Mar 28, 2016. doi: 10.3748/wjg.v22.i12.3372

Table 1 Age, sex, and genotype frequencies of the cases and controls n (%)

Variable	Cases	Controls	P value¹
Variable	n = 727	n = 736	P value¹
Age (mean ± SD), yr	60.3 ± 12.8	60.7 ± 13.0	0.639
Gender			0.751
Male	410 (56.4)	409 (55.6)
Female	317 (43.6)	327 (44.4)
Colon/rectum, n	352/375
OGG1 Ser326Cys			0.021
Ser/Ser	93 (13.0)	125 (17.1)
Ser/Cys	363 (50.8)	324 (44.4)
Cys/Cys	258 (36.1)	281 (38.5)
Missing	13	6
OGG1 11657A/G			0.318
A/A	648 (91.9)	654 (90.1)
A/G	55 (7.8)	72 (9.9)
G/G	2 (0.3)	0 (0.0)
Missing	22	10
OGG1 Arg154His			0.158
Arg/Arg	720 (100.0)	720 (99.7)
Arg/His	0 (0.0)	2 (0.3)
His/His	0 (0.0)	0 (0.0)
Missing	7	14
APE1 Asp148Glu			0.567
Asp/Asp	236 (33.0)	249 (34.3)
Asp/Glu	349 (48.8)	361 (49.7)
Glu/Glu	130 (18.2)	117 (16.1)
Missing	12	9
APE1 T-656G			0.876
T/T	217 (30.1)	211 (28.9)
T/G	368 (51.0)	380 (52.0)
G/G	136 (18.9)	140 (19.2)
Missing	6	5

¹Continuous variables were tested by Student’s t-test, and categorical variables were tested by χ² or Mantel-Haenszel χ² test.

Table 2 Distribution of OGG1 and APE1 polymorphisms between cases and controls n (%)

Genotype	Cases	Controls	OR (95%CI)¹	P value
OGG1 Ser326Cys
Ser/Ser	93 (13.0)	125 (17.1)	1.00 (ref)
Ser/Cys	363 (50.8)	324 (44.4)	1.51 (1.11-2.05)	0.009
Cys/Cys	258 (36.1)	281 (38.5)	1.23 (0.90-1.69)	0.198
Ser/Cys + Cys/Cys	621 (87.0)	605 (82.9)	1.38 (1.03-1.85)	0.030
OGG1 11657A/G
A/A	648 (91.9)	654 (90.1)	1.00 (ref)
A/G	55 (7.8)	72 (9.9)	0.77 (0.53-1.12)	0.168
G/G	2 (0.3)	0 (0.0)	-
A/G + G/G	57 (8.1)	72 (9.9)	0.80 (0.56-1.15)	0.230
APE1 Asp148Glu
Asp/Asp	236 (33.0)	249 (34.3)	1.00 (ref)
Asp/Glu	349 (48.8)	361 (49.7)	1.02 (0.81-1.29)	0.864
Glu/Glu	130 (18.2)	117 (16.1)	1.17 (0.86-1.60)	0.308
Asp/Glu + Glu/Glu	479 (67.0)	478 (65.8)	1.06 (0.85-1.32)	0.615
APE1 T-656G
T/T	217 (30.1)	211 (28.9)	1.00 (ref)
T/G	368 (51.0)	380 (52.0)	0.94 (0.74-1.20)	0.630
G/G	136 (18.9)	140 (19.2)	0.95 (0.70-1.28)	0.731
T/G + G/G	504 (69.9)	520 (71.1)	0.95 (0.75-1.18)	0.621

¹ORs and 95%CIs were estimated from unconditional logistic regressions after controlling for age and sex.

Table 3 Odds ratio and 95%CI of two OGG1 single nucleotide polymorphisms for colorectal cancer stratified by sex, age at diagnosis, and tumor site and stage

	OGG1 Ser326Cys				OGG1 11657A/G
	Ser/Ser		Ser/Cys + Cys/Cys		A/A		A/G + G/G
	No.¹	OR (95%CI)²	No.¹	OR (95%CI)²	No.¹	OR (95%CI)²	No.¹	OR (95%CI)²
Gender
Male	50/67	1.00 (ref)	350/340	1.38 (0.93-2.05)	364/358	1.00 (ref)	31/47	0.65 (0.40-1.05)
Female	43/58	1.00 (ref)	271/265	1.38 (0.90-2.12)	284/296	1.00 (ref)	26/25	1.09 (0.61-1.93)
Age at diagnosis (yr)
≤ 60	44/54	1.00 (ref)	275/264	1.28 (0.83-1.97)	292/283	1.00 (ref)	23/32	0.70 (0.40-1.22)
> 60	49/71	1.00 (ref)	346/341	1.47 (0.99-2.17)	356/371	1.00 (ref)	34/40	0.89 (0.55-1.43)
Tumor site
Colon	45/125	1.00 (ref)	299/605	1.39 (0.96-2.01)	316/654	1.00 (ref)	23/72	0.67 (0.41-1.09)
Rectum	48/125	1.00 (ref)	322/605	1.39 (0.97-1.99)	332/654	1.00 (ref)	34/72	0.93 (0.61-1.43)
Stage
0, I, II	46/125	1.00 (ref)	283/605	1.28 (0.88-1.84)	307/654	1.00 (ref)	20/72	0.59 (0.35-0.98)^a
III, IV	47/125	1.00 (ref)	338/605	1.48 (1.03-2.13)^a	341/654	1.00 (ref)	37/72	0.99 (0.65-1.51)

¹Number of cases/number of controls;

²Adjustment for age and sex (except in gender stratification, where only sex was adjusted for). The

^aP < 0.05 is the comparison between CRC patients in stage 0, I, II and controls in calculating OR for A/G + G/G genotype vs A/A genotype.

Table 4 Odds ratio and 95%CI of two APE1 single nucleotide polymorphisms for colorectal cancer stratified by sex, age at diagnosis, and tumor site and stage

	APE1 Asp148Glu				APE1 T-656G
	Asp/Asp		Asp/Glu + Glu/Glu		T/T		T/G + G/G
	No.¹	OR (95%CI)²	No.¹	OR (95%CI)²	No.¹	OR (95%CI)²	No.¹	OR (95%CI)²
Gender
Male	137/122	1.00 (ref)	264/283	0.83 (0.62-1.12)	128/111	1.00 (ref)	277/296	0.81 (0.60-1.10)
Female	99/127	1.00 (ref)	215/195	1.41 (1.02-1.96)^a	89/100	1.00 (ref)	227/224	1.14 (0.81-1.60)
Age at diagnosis (yr)
≤ 60	105/110	1.00 (ref)	213/205	1.09 (0.78-1.51)	108/99	1.00 (ref)	215/219	0.90 (0.65-1.26)
> 60	131/139	1.00 (ref)	266/273	1.03 (0.77-1.38)	109/112	1.00 (ref)	289/301	0.99 (0.73-1.35)
Tumor site
Colon	114/249	1.00 (ref)	231/478	1.06 (0.81-1.40)	105/211	1.00 (ref)	244/520	0.94 (0.71-1.25)
Rectum	122/249	1.00 (ref)	248/478	1.05 (0.81-1.38)	112/211	1.00 (ref)	260/520	0.95 (0.72-1.24)
Stage
0, I, II	106/249	1.00 (ref)	226/478	1.11 (0.84-1.47)	107/211	1.00 (ref)	226/520	0.85 (0.64-1.12)
III, IV	130/249	1.00 (ref)	253/478	1.02 (0.79-1.33)	110/211	1.00 (ref)	278/520	1.03 (0.79-1.36)

¹Number of cases/number of controls;

²Adjustment for age and sex (except in gender stratification, where only sex was adjusted for). The

^aP < 0.05 is the comparison between CRC cases and controls among female in calculating OR for Asp/Glu + Glu/Glu genotype vs Asp/Asp genotype.

Table 5 Odds ratio and 95%CI of APE1 haplotypes for colorectal cancer stratified by sex, age at diagnosis, and tumor site and stage

	APE1 Asp148Glu/T-656G
	Asp/T		Asp/G		Glu/T		Glu/G
	Ca/Co (%)¹	OR (95%CI)²	Ca/Co (%)¹	OR (95%CI)²	Ca/Co (%)¹	OR (95%CI)²	Ca/Co (%)¹	OR (95%CI)²
All	41.1/41.5	1.00 (ref)	16.3/17.7	0.93 (0.75-1.15)	14.5/13.4	1.09 (0.87-1.37)	28.1/27.5	1.03 (0.86-1.24)
Gender
Male	42.5/40.0	1.00 (ref)	16.0/16.8	0.87 (0.66-1.16)	14.5/14.6	0.91 (0.67-1.22)	27.1/29.7	0.84 (0.66-1.06)
Female	39.3/44.6	1.00 (ref)	16.7/18.9	1.00 (0.73-1.36)	14.5/11.8	1.39 (0.98-1.97)	29.5/24.7	1.36 (1.03-1.78)^a
Age at diagnosis (yr)
≤ 60	42.1/42.7	1.00 (ref)	17.1/17.2	1.01 (0.74-1.38)	15.7/14.8	1.08 (0.77-1.50)	25.0/25.3	1.00 (0.76-1.32)
> 60	40.3/40.5	1.00 (ref)	15.6/18.1	0.87 (0.65-1.15)	13.5/12.3	1.10 (0.81-1.50)	30.6/29.1	1.06 (0.84-1.34)
Tumor site
Colon	40.4/41.5	1.00 (ref)	16.7/17.7	0.96 (0.74-1.25)	15.5/13.4	1.20 (0.91-1.58)	27.4/27.5	1.03 (0.82-1.28)
Rectum	41.7/41.5	1.00 (ref)	16.0/17.7	0.90 (0.69-1.16)	13.5/13.4	0.99 (0.75-1.31)	28.8/27.5	1.04 (0.84-1.29)
Stage
0, I, II	41.1/41.5	1.00 (ref)	15.8/17.7	0.90 (0.69-1.17)	14.9/13.4	1.14 (0.86-1.51)	28.2/27.5	1.02 (0.82-1.28)
III, IV	41.1/41.5	1.00 (ref)	16.7/17.7	0.95 (0.74-1.23)	14.1/13.4	1.06 (0.81-1.39)	28.1/27.5	1.04 (0.84-1.29)

¹Percentage of cases/percentage of controls;

²Adjustment for age and sex (except in gender stratification, where only sex was adjusted for). The

^aP < 0.05 is the comparison between CRC cases and controls among female in calculating OR for Glu/G haplotype vs Asp/T haplotype.

Citation: Lai CY, Hsieh LL, Tang R, Santella RM, Chang-Chieh CR, Yeh CC. Association between polymorphisms of APE1 and OGG1 and risk of colorectal cancer in Taiwan. World J Gastroenterol 2016; 22(12): 3372-3380
URL: https://www.wjgnet.com/1007-9327/full/v22/i12/3372.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i12.3372